drugset / Trial / NCT05279313
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
NaSingle-groupOpen-labelTreatment
Summary
To evaluate long-term safety exposure
Timeline
- Start
- 2022-02-24
- Primary completion
- 2026-04-24
- Completion
- 2026-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Centanafadine | Small molecule | 82.2 mg | — |
| Subject | Centanafadine | Small molecule | 328.8 mg | — |